19:50 EDT Kazia Therapeutics (KZIA) trading halted, news pending Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for ...

CRISPR Therapeutics won its first regulatory approval a little over a year ago, and has compelling candidates in the pipeline. Of course, Vertex's success didn't happen overnight -- and the ...

XORTX Therapeutics (XRTX) announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off ...

JUPITER, Fla. and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq: LGND) and Channel Therapeutics ...

Viking Therapeutics has multiple promising drugs in its portfolio that could generate billions in future revenue. Approval of VK2735 and VK2809 could lead to a surge in the stock's value.

Tvardi Therapeutics, Inc. (Nasdaq: TVRD), a clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrosis-driven diseases, visits the Nasdaq MarketSite in Times Square.

Lambic is a style of beer that has been brewed in Belgium since hundreds of years ago, and today it still remains under that almost magical halo around its production process and the mysterious ...

A source familiar with the situation told the Business Journal that the executive team and board of directors at Lyndra Therapeutics resigned on Tuesday. Lyndra Therapeutics, a drug developer that ...

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific ...

Get Matt’s next trade alert free. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in ...

Summit Therapeutics (NASDAQ:SMMT) traded higher in the premarket on Wednesday after Citi upgraded the stock to Buy from Neutral, becoming the latest brokerage to issue a bullish view on the cancer ...